Aurobindo Pharma’s Joint Venture (JV) company-- Tergene Biotech has received Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) recommendation to manufacture and market 15-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV15) with three dose schedule (3 +0) for administration into the pediatric age group of 6, 10 and 14 weeks.
PCV15 vaccine was developed by Tergene Biotech and manufactured at AuroVaccines, which is a wholly owned subsidiary of Aurobindo Pharma with capabilities in vaccines development and manufacturing. Aurobindo Pharma holds 80% stake in the Joint Venture company, Tergene Biotech.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1509.50 |
Dr. Reddys Lab | 5767.40 |
Cipla | 1407.70 |
Zydus Lifesciences | 999.85 |
Lupin | 1674.45 |
View more.. |